102971-73-3

Basic information

• Product Name: (R)-FMOC-2-AMINO-3-(3-TERT-BUTOXYCARBONYL-PROPYLSULFANYL)-PROPIONIC ACID
• Synonyms: (R)-FMOC-2-AMINO-3-(3-TERT-BUTOXYCARBONYL-PROPYLSULFANYL)-PROPIONIC ACID;Fmoc-L-Cys(tert-butoxycarbonylpropyl)-OH;Fmoc-L-Cys(PrCO-OtBu)-OH;Fmoc-Cys(tertbutoxycarnylpropyl)-OH;(R)-4-[[2-Carboxy-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]ethyl]thio]butanoic acid 1-(1,1-dimethylethyl) ester;(9H-Fluoren-9-yl)MethOxy]Carbonyl Cys(PrCO-OtBu)-OH;(R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((4-(tert-butoxy)-4-oxobutyl)thio)propanoic acid;Fmoc-Cys(C3H6COOtBu)-OH
• CAS NO: 102971-73-3
• Molecular Formula: C₂₆H₃₁NO₆S
• Molecular Weight: 485.59
• Mol File: 102971-73-3.mol

Chemical Properties

• Boiling Point: 673.8±55.0 °C(Predicted)
• Appearance: /
• Density: 1.237±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.47±0.10(Predicted)
• CAS DataBase Reference: (R)-FMOC-2-AMINO-3-(3-TERT-BUTOXYCARBONYL-PROPYLSULFANYL)-PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-FMOC-2-AMINO-3-(3-TERT-BUTOXYCARBONYL-PROPYLSULFANYL)-PROPIONIC ACID(102971-73-3)
• EPA Substance Registry System: (R)-FMOC-2-AMINO-3-(3-TERT-BUTOXYCARBONYL-PROPYLSULFANYL)-PROPIONIC ACID(102971-73-3)

Safety Data

• Hazardous Substances Data: 102971-73-3(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Upstream product

• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 30845-10-4 4-((2R)-amino-2-carboxyethylsulfanyl)butyric acid tert butyl ester 
• 110661-91-1 tert-butyl 4-bromobutyrate 
• 6182-78-1 tert-butyl 4-iodobutanoate 
• 3153-32-0 2-chloroethylacetic acid tert-butyl ester 
• 102774-86-7 9-fluorenylmethyl N-succinimidyl carbonate 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 

Downstream Products

• 1613409-00-9 C₄₆H₇₃N₁₁O₁₂S 
• 1190083-09-0 C₄₆H₇₁N₁₁O₁₂S₂ 
• 1190083-08-9 C₄₆H₇₁N₁₁O₁₃S 
• 1190083-10-3 C₄₇H₇₃N₁₁O₁₂S 
• 1190083-13-6 C₄₆H₇₁N₁₁O₁₂S 
• 37025-55-1 Carbetocin 

Relevant articles and documents

The mimics of Nε-acyl-lysine derived from cysteine as sirtuin inhibitors

Sirtuin inhibitors as physiological research tools and therapeutic potentials have caught many attentions in last decades. The mimics of acyl lysine have been approved to be a very efficient strategy for development of mechanism-based sirtuin inhibitors. In current study, a novel scaffold of L-S-(3-carboxamidopropyl) cysteine (L-CAPC) has been exploited for design and synthesis of sirtuin inhibitors. As a result, the mimics of Nε-acyl-lysine derived from cysteine including small molecules (5a–m) and peptides (9a–m) have been synthesized. Among these, the peptides 9g and 9h were found to be the most inhibitory potency and selectivity against SIRT2.

Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer

Zinc-dependent histone deacetylases (HDACs) are important epigenetic regulators that have become important drug targets for treating cancer. Although five HDAC inhibitors have been approved for treating several cancers, there is still a huge demand on discovering new HDAC inhibitors to explore the therapeutic potentials for treating solid tumor cancers. Substrate mimics are a powerful rational design approach for the development of potent inhibitors. Here we describe the rational design, synthesis, biological evaluation, molecular docking and in vivo efficacy study of a class of HDAC inhibitors using Nε-acetyl lysine mimics that are derived from cysteine. As a result, compounds 7a, 9b and 13d demonstrated pan-HDAC inhibition and broad cytotoxicity against several cancer cell lines, comparable to the approved HDAC inhibitor SAHA. Furthermore, 13d significantly inhibited tumor growth in a A549 xenograft mice model without any obvious weight loss, supporting that the cysteine-derived acetyl lysine mimics are promising HDAC inhibitors with therapeutic potentials for treating cancer.

Antiproliferative and phenotype-transforming antitumor agents derived from cysteine

Selective destruction of malignant tumor cells without damaging normal cells is an important goal for cancer chemotherapy in the 21st century. Differentiating agents that transform cancer cells to either a nonproliferating or normal phenotype could potent

Lysine derivative histone deacetylase inhibitor, synthesis and application

The invention discloses a lysine derivative histone deacetylase inhibitor. The inhibitor has high selectivity, can be used for Sirtuin mechanism inhibitor antitumor drugs with strong Sirtuin selectivity, high efficiency and low toxicity, has easily available raw materials, and is low in cost.

1-deamino-1(15)-carba and -dicarba analogues of endothelin-1

Sulfanyl-methylene and ethylene bridges were inserted into the molecule of endothelin-1 (ET-1) as other possible isosteric replacements of its outer disulfide linkage. The [1-deamino-1-carba]ET-1, [1-deamino-15-carba]ET-1 and [1-deamino-1,15-dicarba]ET-1 were synthesized either by a fragment condensation of protected cyclic pentadecapeptides with carboxy-terminal hexapeptides of the endothelin-1 sequence or by step-wise coupling on polymer support of the entire henicosapeptide sequences from carboxy-terminus. The analogues were devoid of uterotonic activity in comparison with the parent ET-1.

ANALOGS OF DEAMINO CARBA OXYTOCIN WITH INHIBITORY PROPERTIES; SYNTHESIS AND BIOLOGICAL ACTIVITIES

Solid phase methodology on polyamide-kieselguhr resin was used for the synthesis of six analogs of deamino carba-1 or carba-6 oxytocin with non-coded amino acids in position 2, threonine in position 4, ornithine in position 8 and without glycine in positi